These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 24689365)

  • 41. An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques.
    Fernandez S; Thomas SJ; De La Barrera R; Im-Erbsin R; Jarman RG; Baras B; Toussaint JF; Mossman S; Innis BL; Schmidt A; Malice MP; Festraets P; Warter L; Putnak JR; Eckels KH
    Am J Trop Med Hyg; 2015 Apr; 92(4):698-708. PubMed ID: 25646261
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Virus-like particles displaying envelope domain III of dengue virus type 2 induce virus-specific antibody response in mice.
    Arora U; Tyagi P; Swaminathan S; Khanna N
    Vaccine; 2013 Jan; 31(6):873-8. PubMed ID: 23261049
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-Term Protection Elicited by a DNA Vaccine Candidate Expressing the prM-E Antigen of Dengue Virus Serotype 3 in Mice.
    Feng K; Zheng X; Wang R; Gao N; Fan D; Sheng Z; Zhou H; Chen H; An J
    Front Cell Infect Microbiol; 2020; 10():87. PubMed ID: 32257963
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Precisely Molded Nanoparticle Displaying DENV-E Proteins Induces Robust Serotype-Specific Neutralizing Antibody Responses.
    Metz SW; Tian S; Hoekstra G; Yi X; Stone M; Horvath K; Miley MJ; DeSimone J; Luft CJ; de Silva AM
    PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005071. PubMed ID: 27764114
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluation of interferences between dengue vaccine serotypes in a monkey model.
    Guy B; Barban V; Mantel N; Aguirre M; Gulia S; Pontvianne J; Jourdier TM; Ramirez L; Gregoire V; Charnay C; Burdin N; Dumas R; Lang J
    Am J Trop Med Hyg; 2009 Feb; 80(2):302-11. PubMed ID: 19190230
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nucleocapsid-like particles of dengue-2 virus enhance the immune response against a recombinant protein of dengue-4 virus.
    Lazo L; Gil L; Lopez C; Valdes I; Marcos E; Alvarez M; Blanco A; Romero Y; Falcon V; Guzmán MG; Guillén G; Hermida L
    Arch Virol; 2010 Oct; 155(10):1587-95. PubMed ID: 20640909
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dengue-1 envelope protein domain III along with PELC and CpG oligodeoxynucleotides synergistically enhances immune responses.
    Chiang CY; Huang MH; Hsieh CH; Chen MY; Liu HH; Tsai JP; Li YS; Chang CY; Liu SJ; Chong P; Leng CH; Chen HW
    PLoS Negl Trop Dis; 2012; 6(5):e1645. PubMed ID: 22616020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice.
    Zheng X; Chen H; Wang R; Fan D; Feng K; Gao N; An J
    Front Cell Infect Microbiol; 2017; 7():175. PubMed ID: 28553618
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of chimeric DNA vaccines consisting of premembrane and envelope genes of Japanese encephalitis and dengue viruses as a strategy for reducing induction of dengue virus infection-enhancing antibody response.
    Sjatha F; Kuwahara M; Sudiro TM; Kameoka M; Konishi E
    Microbiol Immunol; 2014 Feb; 58(2):126-34. PubMed ID: 24372832
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A dengue DNA vaccine formulated with Vaxfectin® is well tolerated, and elicits strong neutralizing antibody responses to all four dengue serotypes in New Zealand white rabbits.
    Raviprakash K; Luke T; Doukas J; Danko J; Porter K; Burgess T; Kochel T
    Hum Vaccin Immunother; 2012 Dec; 8(12):1764-8. PubMed ID: 23032166
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant nucleocapsid-like particles from dengue-2 virus induce protective CD4+ and CD8+ cells against viral encephalitis in mice.
    Gil L; López C; Lazo L; Valdés I; Marcos E; Alonso R; Gambe A; Martín J; Romero Y; Guzmán MG; Guillén G; Hermida L
    Int Immunol; 2009 Oct; 21(10):1175-83. PubMed ID: 19692540
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Broad neutralization of wild-type dengue virus isolates following immunization in monkeys with a tetravalent dengue vaccine based on chimeric yellow fever 17D/dengue viruses.
    Barban V; Munoz-Jordan JL; Santiago GA; Mantel N; Girerd Y; Gulia S; Claude JB; Lang J
    Virology; 2012 Aug; 429(2):91-8. PubMed ID: 22542002
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A MVA construct expressing a secretable form of the Dengue virus 3 envelope protein protects immunized mice from dengue-induced encephalitis.
    Quinan BR; Versiani AF; da Fonseca FG
    Vaccine; 2016 Dec; 34(50):6120-6122. PubMed ID: 27817963
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy of a tetravalent chimeric dengue vaccine (DENVax) in Cynomolgus macaques.
    Osorio JE; Brewoo JN; Silengo SJ; Arguello J; Moldovan IR; Tary-Lehmann M; Powell TD; Livengood JA; Kinney RM; Huang CY; Stinchcomb DT
    Am J Trop Med Hyg; 2011 Jun; 84(6):978-87. PubMed ID: 21633037
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation in Mice of the Immunogenicity of a Tetravalent Subunit Vaccine Candidate Against Dengue Virus Using Mucosal and Parenteral Immunization Routes.
    Lazo Vázquez L; Gil González L; Marcos López E; Pérez Fuentes Y; Cervetto de Armas L; Brown Richards E; Valdés Prado I; Suzarte Portal E; Cobas Acosta K; Yaugel Novoa M; Romero Fernández Y; Guillén Nieto G; Hermida Cruz L
    Viral Immunol; 2017 Jun; 30(5):350-358. PubMed ID: 28418786
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.
    Blaney JE; Sathe NS; Hanson CT; Firestone CY; Murphy BR; Whitehead SS
    Virol J; 2007 Feb; 4():23. PubMed ID: 17328799
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
    Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.
    Keelapang P; Nitatpattana N; Suphatrakul A; Punyahathaikul S; Sriburi R; Pulmanausahakul R; Pichyangkul S; Malasit P; Yoksan S; Sittisombut N
    Vaccine; 2013 Oct; 31(44):5134-40. PubMed ID: 23973247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.